We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

71 hedge funds and large institutions have $202M invested in AEON Biopharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $192M → $202M (+$10.3M)

0.05% more ownership

Funds ownership: 0.99% → 1.04% (+0.05%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

3% less funds holding

Funds holding: 73 → 71 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$9.74M
2
SC
Sculptor Capital
New York
+$4.67M
3
SCM
Saba Capital Management
New York
+$4.21M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.47M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$4.99M
2
Blackstone Inc
Blackstone Inc
New York
-$4.48M
3
Wells Fargo
Wells Fargo
California
-$2.76M
4
MP
Mangrove Partners
Connecticut
-$2.06M
5
ACA
Arena Capital Advisors
California
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
51
Segantii Capital Management
Hong Kong
$489K – – –
TCM
52
Tegean Capital Management
New York
$489K – – –
Ohio Public Employees Retirement System (OPERS)
53
Ohio Public Employees Retirement System (OPERS)
Ohio
$489K +$487K +694 New
CCM
54
Context Capital Management
California
$485K +$483K +689 New
CSS
55
Cubist Systematic Strategies
Connecticut
$410K +$176K +251 +76%
Blackstone Inc
56
Blackstone Inc
New York
$393K -$4.48M -6,386 -92%
RCM
57
Rivernorth Capital Management
Florida
$391K – – –
NAM
58
Nexpoint Asset Management
Texas
$389K – – –
BCM
59
Basso Capital Management
Connecticut
$374K – – –
GH
60
GAM Holding
Switzerland
$328K – – –
ICMH
61
Integrity Capital Management (HK)
Hong Kong
$293K – – –
Citigroup
62
Citigroup
New York
$245K – – –
WRBC
63
W.R. Berkley Corp
Connecticut
$245K – – –
CCM
64
Cinctive Capital Management
New York
$244K – – –
DFCM
65
Dark Forest Capital Management
Puerto Rico
$243K -$75.7K -108 -24%
KKRC
66
Kohlberg Kravis Roberts & Co
New York
$217K +$114K +162 +111%
RCM
67
Robinson Capital Management
Michigan
$211K – – –
TI
68
Tidal Investments
Wisconsin
$211K – – –
AA
69
Ancora Advisors
Ohio
$164K – – –
6CM
70
683 Capital Management
New York
$98K – – –
UBS Group
71
UBS Group
Switzerland
$11K +$10.5K +15 New
UOC
72
UBS O'Connor
Illinois
– -$4.99M -7,136 Closed
Wells Fargo
73
Wells Fargo
California
– -$2.76M -3,945 Closed
MP
74
Mangrove Partners
Connecticut
– -$2.06M -2,944 Closed
FIG
75
Fortress Investment Group
New York
– -$1.46M -2,083 Closed
1 2
3
4

AEON Hedge Fund Activity: Q1 2022 in Review

71 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2022, worth a combined $202M — up 5.4% from $192M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AEON and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 12 added.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $9.74M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.99M sold.

  • 71 institutional investors held AEON Biopharma (AEON) as of Q1 2022, down from 73 in Q4 2021.
  • Funds reported $202M of AEON Biopharma stock for Q1 2022, up 5.4% quarter-over-quarter.
  • 8 funds opened new AEON Biopharma positions in Q1 2022 and 10 closed out, a net change of -2 holders.
  • The largest AEON Biopharma buyer in Q1 2022 was Aristeia Capital, an estimated $9.74M added.
  • The largest AEON Biopharma seller in Q1 2022 was UBS O'Connor, an estimated $4.99M sold.

Based on aggregated 13F filings for Q1 2022.